An interventional study of craniospinal irradiation in Glioma, sponsored by Tata Memorial Centre. Recruiting at 1 site in India. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-01-20.
Sponsored by Tata Memorial Centre · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Glioma with a site in India — 8 open to participants now, 8 under way, none of them phase 3. Glioma · India.
Among the 19 studies in Glioma with a site in India, this one is one of 3 that started in 2025, is one of 4 with no phase, and was the 11th registered.
1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.
Browse Glioma studies →8 of the 19 studies in Glioma with a site in India are open now. Recruiting first, the newest first:
Tata Memorial Centre · Sites in India
Ages 5+
Tata Memorial Centre · Sites in India
Ages 50+
Tata Memorial Centre · Sites in India
Ages 5–39
Tata Memorial Centre · Sites in India
Ages 1+
Tata Memorial Centre · Sites in India
Ages 18–70
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.
This study: 3 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 32 is close to the median of 32 across 1,078 interventional studies indexed under Glioma.
Median enrollment 35 across the 7 interventional studies, 1,186 across the 12 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 19 have an industry lead sponsor. The 8 most frequent:
Tata Memorial Centre is the lead sponsor of 64 studies on the registry; 42 are open to participants now.
Tata Memorial Centre has 7 studies filed under Glioma — fewer than ten, so there is no comparison to draw.
2 of the studies in Glioma with a site in India that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06036381Tata Memorial CentreSpatial and Temporal Characterization of Gliomas Using Radiomic Analysis | 2026-12 |
| NCT07236840Tata Memorial CentreSelf-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Glioma with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Paediatric H3K27/H3G34 mutant diffuse midline gliomas are high grade gliomas that arise in midline structures/cerebral hemispheres and are known to have dismal outcomes. Standard treatment includes definitive radiation therapy to primary site along with concurrent temozolomide chemotherapy following histological confirmation with a biopsy. Studies have shown poorer outcomes in the paediatric age group compared to that of adults and an increased risk to fail/recur in the leptomeninges(covering of brain and spinal cord). The following study is planned in order to assess the benefit of craniospinal irradiation(delivering radiotherapy to brain, spinal cord and its covering membrane in this high risk population. Thereby the investigator aim to improve survival in newly diagnosed histone mutant pediatric midline gliomas in the upfront setting. Patterns of disease failure, treatment related toxicities and quality of life will also be assessed as a part of this study. If proven beneficial, this study will influence how patients with this diagnosis will be treated in the future.
Introduction: Paediatric H3K27/H3G34 mutant diffuse midline gliomas (DMGs) are aggressive high-grade gliomas predominantly affecting midline structures and cerebral hemispheres. Despite aggressive therapy including radiation and chemotherapy, these tumors carry a poor prognosis, particularly in children, with frequent recurrence and high risk of leptomeningeal spread. Current standard treatment involves definitive radiation therapy to the primary site and concurrent temozolomide chemotherapy following histological confirmation via biopsy. However, outcomes remain suboptimal, prompting exploration of more intensive therapeutic strategies.
Primary objective:
To study if the addition of craniospinal irradiation to standard practice improves outcomes in pediatric diffuse midline glioma.
Secondary objectives:
Primary endpoint: Overall survival at 12 months
Secondary endpoints:
Study setting: The study will be conducted in the department of Radiation Oncology, Neuro Oncology Disease management group
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Craniospinal irradiation involves delivery of radiation therapy to the whole brain, spinal cord, nerve roots, the covering meninges(leptomeninges) and subarachnoid space and provides a viable means of mitigating leptomeningeal spread and possibly improving survival.
Radiation: craniospinal irradiation
Delivering radiotherapy to brain, spinal cord and its covering membrane.
Survival Outcomes
Overall survival- time in months between the date of diagnosis to date of death due to any cause
Time frame: at 12 months
Leptomeningeal Dissemination
Time to leptomeningeal dissemination (will be defined as time in months between completion of planned therapy to the date of confirmation of leptomeningeal metastasis)
Time frame: at 12 months
Patterns of failure
Incidence of different patterns of failure from diagnosis ( the time point of measurement of the primary outcome - overall survival
Time frame: at 12 months
Any treatment emergent acute toxicity recording
All treatment emergent acute toxicity- expected (nausea, vomiting, hematological, dermatitis and mucositis) and unexpected, will be recorded. Grading will be done for all using the Common Terminology Criteria for Adverse Events (CTCAE) Version 5
Time frame: Baseline , week 1 , week 2 , week 3 , week 4 , week 5 ,week 6 , conclusion of RT
Quality of life indices
Objective scoring with European Organisation For Research And Treatment Of Cancer(EORTC) Quality of Life Questionnaire(QLQC-30), brain specific module (BN 20)
Time frame: will be done at 3 months
QTWiST (Quality of life Without Symptoms or Toxicity) calculation
Objective score calculation using mean duration in each health state weighed by a utility coefficient; from QLQC 30- BN 20 scores and the time spent in serious toxicity and without relapse.
Time frame: will be done at 3 months
Any treatment emergent late toxicity recording
All treatment emergent late toxicity- expected and unexpected, will be recorded after completion of chemotherapy. Grading will be done for all using the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.
Time frame: After completion of 6 cycles of adjuvant chemotherapy, at 3months, 6months, 9months and 12months follow up
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Nov 2028, 46 months after the start.
Of 131 non-industry interventional studies with no phase under Glioma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 114. This study's planned 46 months is below that.
Counting every sponsor, half of 142 studies reached it within 58 months; a quarter within 34 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tata Memorial Centre